01.09.2016 • News

Avantor and NuSil Agree to Merge

US firms Avantor Performance Materials and NuSil Technology have agreed to merge. Both are majority held by New York-based private equity fund New Mountain Capital which will remain as the major owner post-merger. The deal will create the global leader in ultra-high purity materials for the life sciences and advanced technology markets. Combined revenues will be above $700 million, and growing at 14% per year.

To be called Avantor, the new company will provide performance materials and solutions for the production and research needs of more than 6,500 customers across a variety of industries including biotechnology, pharmaceutical, medical device, diagnostics, aerospace & defense, and semi-conductor.

In addition, the combination of complementary technologies and advanced analytical capabilities will create a portfolio of more than 30,000 products which meet increasingly stringent standards across markets that are technology-driven and highly regulated.

New Mountain Capital’s managing director, Matt Holt, said the two companies had seen a positive transformation during its ownership, with strong organic growth and attractive margins. “The combined company will have strong positions across the drug lifecycle value chain including particular strengths in the bioprocessing and biomaterials segments, which we see as two highly attractive end markets that increasingly converge,” he said.

The investment firm bought into Avantor and Nusil in 2010 and 2011, respectively. Completion is expected in late September, subject to the usual closing conditions. Financial terms were not disclosed.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.